VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
CssBA
Phase 2
Biologic
N
National Institute of Allergy and Infectious Diseases (NIAID)
1
Indications
2
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Diarrhea
1 trial
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults
Active, not recruiting
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 2
·
NCT06692907
·
72 enrolled
Vaccine
1 trial
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
Completed
·
P
PATH
·
Phase 1
·
NCT03404674
·
50 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for CssBA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
CssBA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for CssBA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Phase 2
[1]
Company
N
National Institute of Allergy and Infectious Diseases (NIAID)
Related News